Cardiometabolic risk in children and adolescents with obesity: a position paper of the Italian Society for Pediatric Endocrinology and Diabetology
- PMID: 39380079
- PMCID: PMC11463079
- DOI: 10.1186/s13052-024-01767-x
Cardiometabolic risk in children and adolescents with obesity: a position paper of the Italian Society for Pediatric Endocrinology and Diabetology
Abstract
Despite the implementation of preventive measures to counteract the obesity epidemics, the prevalence of childhood obesity is still alarming all over the world. Childhood obesity is the most common risk factor for both cardiovascular and metabolic diseases. In fact, an earlier onset of obesity can cause a greater risk of adiposity tracking across the lifespan and consequently a longer exposure to cardiometabolic risk factors. Accumulating evidence provided by prospective and intervention studies demonstrated the link between pediatric obesity and selected subclinical signs of cardiovascular damage (atherosclerosis and left ventricular hypertrophy), or fatal and not fatal cardiovascular events as early as 40 years of age.The numerous guidelines and scientific documents published in the last years demonstrate the relevance of assessing cardiometabolic risk factors in children and adolescents with OB.This Position paper, released by experts of the "Childhood Obesity study group" within the Italian Society for Pediatric Endocrinology and Diabetology, aims to review the assessment of cardiometabolic risk factors and comorbidities in children and adolescents with OW/OB on the light of the most recent scientific evidence.The main recommendations are: (a) early detection of comorbidities, including hypertension, dyslipidemia, prediabetes/type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, polycystic ovary syndrome, inactivity, obstructive sleep apnea and decline in kidney function; (b) weight loss treatment, which is associated with a reduction of all cardiometabolic risk factors; (c) specific treatment of comorbidities, through lifestyle modifications or pharmacological treatment added to lifestyle for suitable individuals; d). monitoring comorbidities for mitigating future morbidity and mortality.
Keywords: Cardiometabolic risk; Dyslipidemia; Hypertension; Kidney disease; Left ventricular hypertrophy; Metabolic dysfunction-associated steatotic liver disease; Obstructive sleep apnea; Pediatric obesity; Physical inactivity; Polycystic ovary syndrome.
© 2024. The Author(s).
Conflict of interest statement
C.M. is Associate Editor (Section of Pediatric Endocrinology and Diabetology) for the Italian Journal of Pediatrics.
Similar articles
-
Practice Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease by the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN).Indian Pediatr. 2024 Oct 15;61(10):919-934. Epub 2024 Sep 13. Indian Pediatr. 2024. PMID: 39297398
-
Childhood obesity classification systems and cardiometabolic risk factors: a comparison of the Italian, World Health Organization and International Obesity Task Force references.Ital J Pediatr. 2017 Feb 4;43(1):19. doi: 10.1186/s13052-017-0338-z. Ital J Pediatr. 2017. PMID: 28257654 Free PMC article.
-
Resolving early obesity leads to a cardiometabolic profile within normal ranges at 23 years old in a two-decade prospective follow-up study.Sci Rep. 2021 Sep 23;11(1):18927. doi: 10.1038/s41598-021-97683-9. Sci Rep. 2021. PMID: 34556688 Free PMC article.
-
Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics.Ital J Pediatr. 2018 Jul 31;44(1):88. doi: 10.1186/s13052-018-0525-6. Ital J Pediatr. 2018. PMID: 30064525 Free PMC article. Review.
-
Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity.Cardiovasc Diabetol. 2020 Jun 13;19(1):79. doi: 10.1186/s12933-020-01052-1. Cardiovasc Diabetol. 2020. PMID: 32534575 Free PMC article.
Cited by
-
The Role of Nutraceuticals and Probiotics in Addition to Lifestyle Intervention in the Management of Childhood Obesity-Part 2: Comorbidities.Nutrients. 2025 Apr 28;17(9):1487. doi: 10.3390/nu17091487. Nutrients. 2025. PMID: 40362796 Free PMC article. Review.
-
Kidney Damage in Pediatric Obesity: Insights from an Emerging Perspective.J Clin Med. 2024 Nov 21;13(23):7025. doi: 10.3390/jcm13237025. J Clin Med. 2024. PMID: 39685484 Free PMC article.
-
Key Gaps in the Prevention and Treatment of Obesity in Children and Adolescents: A Critical Appraisal of Clinical Guidelines.Children (Basel). 2025 Mar 10;12(3):347. doi: 10.3390/children12030347. Children (Basel). 2025. PMID: 40150629 Free PMC article. Review.
-
The Role of Nutraceuticals and Probiotics in Addition to Lifestyle Intervention in the Management of Childhood Obesity-Part 1: Metabolic Changes.Nutrients. 2025 May 9;17(10):1630. doi: 10.3390/nu17101630. Nutrients. 2025. PMID: 40431370 Free PMC article. Review.
-
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges.J Clin Med. 2025 Jun 2;14(11):3911. doi: 10.3390/jcm14113911. J Clin Med. 2025. PMID: 40507673 Free PMC article. Review.
References
-
- EpiCentro. Istituto Superiore Sanità (ISS). OKKio alla salute. Dati nazionali e regionali 2019. https://www.epicentro.iss.it/okkioallasalute/indagine-2019-dati
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous